Subscribe
jiris-shutterstock-com
jiris / Shutterstock.com
19 October 2015Americas

Federal Circuit denies rehearing in ‘patent dance’ case

The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit says ‘patent dance’ is optional
22 July 2015   The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.
Americas
Sandoz launches Zarxio biosimilar
4 September 2015   Drug maker Sandoz has officially launched its Zarxio biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.
Americas
Sandoz appeals to US Supreme Court over ‘patent dance’ ruling
17 February 2016   Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Federal Circuit says ‘patent dance’ is optional
22 July 2015   The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.
Americas
Sandoz launches Zarxio biosimilar
4 September 2015   Drug maker Sandoz has officially launched its Zarxio biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.
Americas
Sandoz appeals to US Supreme Court over ‘patent dance’ ruling
17 February 2016   Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.

More on this story

Americas
Federal Circuit says ‘patent dance’ is optional
22 July 2015   The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.
Americas
Sandoz launches Zarxio biosimilar
4 September 2015   Drug maker Sandoz has officially launched its Zarxio biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.
Americas
Sandoz appeals to US Supreme Court over ‘patent dance’ ruling
17 February 2016   Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York